Search hospitals

>

Hawaii

>

Honolulu

Cancer Research Center of Hawaii

Claim this profile

Honolulu, Hawaii 96813

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Cancer

Conducts research for Breast cancer

Conducts research for Leukemia

421 reported clinical trials

17 medical researchers

Photo of Cancer Research Center of Hawaii in HonoluluPhoto of Cancer Research Center of Hawaii in Honolulu

Summary

Cancer Research Center of Hawaii is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Leukemia and other specialties. Cancer Research Center of Hawaii is involved with conducting 421 clinical trials across 428 conditions. There are 17 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Jared D. Acoba, Jami A. Fukui, and Michael Carney, MD.

Area of expertise

1

Breast Cancer

Global Leader

Cancer Research Center of Hawaii has run 87 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
ER positive
HER2 negative
2

Lung Cancer

Global Leader

Cancer Research Center of Hawaii has run 68 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Cancer Research Center of Hawaii

Lung Cancer

Breast Cancer

Cancer

Breast cancer

Ovarian Cancer

Esophageal cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Laryngeal Cancer

Prostate Cancer

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cancer Research Center of Hawaii?

Where is Cancer Research Center of Hawaii located?

Who should I call to ask about financial aid or insurance network?

What insurance does Cancer Research Center of Hawaii accept?

What awards or recognition has Cancer Research Center of Hawaii received?